

Haematologica  
HAEMATOL/2017/168666  
Version 5

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Luis A Corchete, Irena Misiewicz-Krzeminska, Montserrat Martín-Sánchez, Ana-Alicia López-Iglesias, Esperanza-Macarena Algarín, Pedro Mogollón, Andrea Díaz-Tejedor, Teresa Paíno, Brian Tunquist, María-Victoria Mateos, Norma C Gutiérrez, Elena Díaz-Rodríguez, Mercedes Garayoa, and Enrique M Ocio

Disclosures: EMO and MVM disclose consultancy for Array BioPharma. BT is an employee of Array BioPharma. The remaining authors declare no competing interests. This work was funded in part by Array BioPharma, by the Spanish ISCIII-FIS (PI 15/0067 and PI 15/2156) and FEDER, the Spanish RTICC (RD12/0036/0058), Spanish Association Against Cancer (AECC, GCB120981SAN) and the Regional Council of Castilla y León (GRS 1029/A/14, GRS 1175/A/15 and FIC335U14).

Contributions: SHG, BT, MG and EMO planned the research and wrote the paper. SHG, LSS, LGM performed the experiments. EDR, IM, MMS, AALI, EMA, PM, ADT and TP contributed to the data analysis. LAC analyzed the microarray data. NCG, MVM and EMO provided clinical samples and contributed to the clinical data. All authors reviewed and approved the manuscript.